GLPwatch
Papers (10401)
Page 38 of 174, ranked by citation count.
- GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
- Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
- Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
- Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
- Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.
- Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
- Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
- Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.
- Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.
- Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.
- Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.
- GLP-1 as a target for therapeutic intervention.
- 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake.
- Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
- PET-Based Human Dosimetry of <sup>68</sup>Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging.
- Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
- Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
- Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
- Obesity and GLP-1.
- Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.
- Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
- Weight loss efficiency and safety of tirzepatide: A Systematic review.
- Current Drug Targets in Obesity Pharmacotherapy - A Review.
- Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes.
- Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
- Semaglutide and the risk of diabetic retinopathy-current perspective.
- Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
- GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK.
- Long-acting amylin analogues for the management of obesity.
- Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway.
- Estimands, Estimators, and Estimates.
- Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.
- Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.
- Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
- Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
- Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.
- Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
- Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
- Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
- Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
- Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice.
- Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke.
- In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
- Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.
- The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
- Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes.
- Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.
- Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery.
- Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages.
- Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Pancreatic insulin and exocrine secretion are under the modulatory control of distinct subpopulations of vagal motoneurones in the rat.
- High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
- Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
- Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.